pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,132
stories
25d
FDA extends review of Exelixis' colorectal cancer drug candidate
endpoints
25d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
25d
STAT+: Cancer drug shortages keep disrupting patient care
stat
25d
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
25d
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
25d
mRNA cancer vaccines’ biggest barriers to market
biopharma dive
25d
Beyond clinical endpoints: Rethinking ALS drug development through disease biology
fiercebiotech
25d
The future of RAS inhibitors
fiercebiotech
25d
FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
fiercebiotech
25d
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
stat
25d
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
fiercebiotech
25d
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
25d
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
fiercebiotech
25d
STAT+: Right before midterms, Trump dangles $500 refunds for select ACA enrollees
stat
25d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
25d
Takeda’s long-term R&D head announces exit after major pipeline reorganization
biospace
26d
FDA places partial hold on Biohaven’s epilepsy drug
biopharma dive
26d
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
biopharma dive
26d
STAT+: Can AI save rural health care?
stat
26d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
26d
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
biospace
26d
STAT+: FDA expands Bayer lung cancer drug approval
stat
26d
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
biospace
26d
Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagree
stat
26d
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
fiercebiotech
26d
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
fiercebiotech
26d
For PDUFA VIII, the most valuable incentive may be time
biospace
26d
STAT+: U.K. unveils recommendations for regulating AI in medicine
stat
27d
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
27d
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
biospace
← prev
page 9 of 38
next →
